In IBD IL-32α was elevated in the mucosa (40) (reviewed (3)), whilst in atopic dermatitis, serum levels of IL-32 correlated to severity and were reduced with successful treatment (41), potentially implicating IL-32 as a useful biomarker for disease progression and favorable therapy responses. This evidence concerns the gene IL32 and inflammatory bowel disease.